A Phase 1/2 interventional study of DA-020 and Placebo in Chemotherapy Induced Alopecia and Chemotherapy Side Effects, sponsored by Applied Biology, Inc.. Recruiting at 2 sites in 2 countries. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Applied Biology, Inc. · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Alopecia by Applied Biology, Inc. — 3 open to participants now, 3 under way, 2 of them phase 3. Alopecia · Applied Biology, Inc..
Among the 13 studies in Alopecia by Applied Biology, Inc., this one is one of 3 that started in 2026, is the only one in phase 1/2, and was the 12th registered.
512 studies on the registry are indexed under Alopecia; 128 are open to participants now.
Browse Alopecia studies →3 of the 13 studies in Alopecia by Applied Biology, Inc. are open now, in 2 countries. Recruiting first, the newest first:
Applied Biology, Inc. · Sites in Italy
Ages 18–65 · Women only
Applied Biology, Inc.
Ages 18+
By country, each count listing its studies:
Of the 76 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 48 (63%) stop at 75 or younger; 10 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 4
First in 2014; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 60 across the 9 interventional studies, 150 across the 4 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
Applied Biology, Inc. is the lead sponsor of 25 studies on the registry; 5 are open to participants now.
2 of the studies in Alopecia by Applied Biology, Inc. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06648850Phase 3Applied Biology, Inc.Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth | 2027-03-19 |
| NCT07397325Applied Biology, Inc.Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia | 2027-02-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Alopecia by Applied Biology, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
Clinical Study of DA-020 as a Treatment for Chemotherapy Induced Alopecia
Chemotherapy induced alopecia (CIA) is a common adverse event of oncological treatment. The significant psychological burden of CIA, particularly in women, leads some (\~8%) to reject life saving therapeutic regimens. Several studies have demonstrated the effectiveness of scalp vasoconstriction as a prophylactic treatment for CIA. Recently, US Food and Drug Administration (FDA) approved a scalp-cooling device as a prophylactic treatment for CIA. Scalp cooling results in reduced local blood perfusion and consequently reduced chemotherapeutic agents reaching the hair follicle niche; however, scalp cooling requires prolongation of the time required to attend the chemotherapy unit (>2 hrs) as well as common adverse events including intolerance to cold. A previous study demonstrated that the α1 agonist, phenylephrine hydrochloride, applied topically can penetrate the scalp and bind α1 receptors. As such, a topically applied α1 agonist would reduce scalp blood perfusion. A novel formula (DA-020), containing an α1 agonist, that can also penetrate the scalp and bind α1 receptors. The aim of the study is to test the hypothesis that DA-020 can reduce scalp blood perfusion and thus reduce hair loss due to chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Topical DA-020 Solution
Drug: DA-020
Topical Placebo Solution
Drug: Placebo
DA-020 and Hyperforin (1.5%)
Drug: DA-020 and Hyperforin
7mL application of DA-020 (Topical Oxymetazoline)
Topical placebo solution
7mL application of DA-020 (Topical Oxymetazoline) and Hyperforin (1.5%)
Prevention of Hair Loss (Common Terminology Criteria for Adverse Events V5.0)
Amount of hair loss during chemotherapy treatment measured by the Common Terminology Criteria for Adverse Events (CTCAE) V5.0. The Common Terminology Criteria for Adverse Events is a common terminology developed by the National Cancer Institute to describe and grade adverse events related to cancer therapy.
Time frame: Week [0,12]
Hair Re-Growth Post Treatment (Common Terminology Criteria for Adverse Events V5.0)
Amount of hair re-growth post chemotherapy treatment measured by the Common Terminology Criteria for Adverse Events (CTCAE) V5.0. The Common Terminology Criteria for Adverse Events is a common terminology developed by the National Cancer Institute to describe and grade adverse events related to cancer therapy.
Time frame: Week [12, 24]
Plan to share: No
Started May 2026 (actual). Primary completion is estimated for Feb 2027, 8 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.